WHO ICTRP trial
Evaluation of the Effectiveness of Two Different Regimens Based on Tosilizumab…
IRCT20151227025726N30 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20151227025726N30 |
|---|---|
| Public title | Evaluation of the Effectiveness of Two Different Regimens Based on Tosilizumab and Baricitinib in Patients with COVID-19 |
| Scientific title | Evaluation of the Effectiveness of Two Different Regimens Based on Tosilizumab and Baricitinib in Patients with COVID-19 Respiratory Distress Syndrome |
| Primary sponsor | Shahid Beheshti University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | COVID-19 pneumonia. COVID-19, virus identified;U07.1 |
| Interventions | Intervention 1: Intervention group: In addition to receiving tosilizumab at a dose of 400 mg by slow intravenous injection, patients receive baricitinib as a dose of 4 mg daily for 14 days or until discharge. Intervention 2: Control group… |
| Registration date | Feb 28, 2022 |
| Target size | 60 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: